Zu, Li, Author at MediaMedic

$ASCO China Voice | Professor Zhiming Li: First Phase I Clinical Study Results of a CCR8-Targeting Antibody Drug for Relapsed/Refractory Cutaneous T-Cell Lymphoma Announced$

ASCO China Voice | Professor Zhiming Li: First Phase I Clinical Study Results of a CCR8-Targeting Antibody Drug for Relapsed/Refractory Cutaneous T-Cell Lymphoma Announced

By Zu, Li 2025.07.31

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignant lymphoma originating from the skin and evolving from T-cells. It accounts for approximately 4% of non-Hodgkin lymphoma cases, classifying it as a…

Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy

By Zu, Li 2025.06.04

Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…

Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy

By Zu, Li 2025.06.04

Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…